Medtronic plc. (MDT)

NYSE · Medical Devices

92.85
+2.20 (+2.43%)
Updated Sep 1, 6:30 PM ET
AI Rating
Buy
Overall Score
67
Trend
70
Momentum
57
Risk
77

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Aug 18, 2025 260 sessions Aug 28, 2026

AI Analysis

Medtronic plc. is trading at $92.85, up 2.43% on the session. The 50 day average sits at $85.49 and the 200 day at $89.81, which puts the stock in a downtrend. RSI is at 57, which reads as strong, and MACD is bearish crossover. Volume is average.

The nearest support is around $83.84 with resistance near $94.72, so that band frames the current range. Average daily movement is roughly $2.02, or about 2.2% of the share price, which is what any stop placement has to allow for. The overall health score of 67 out of 100 combines a trend score of 70, momentum of 57 and a risk score of 77.

Technical indicators

RSI (14)
57.0
strong
MACD
1.868
bearish crossover
SMA 20
90.22
SMA 50
85.49
SMA 200
89.81
downtrend
ATR (14)
2.02
avg daily range
Support
83.84
Resistance
94.72
Volume vs 20d
0.96x
average
Volatility
22.0%
annualised
1 month
+6.44%
3 months
+23.60%

About Medtronic plc.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.